Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
The answer, before the caveats
A behavioral health feasibility study is a pre-launch diligence report that quantifies demand, payer mix, competitive saturation, licensure pathway, real estate viability, and pro forma economics for a proposed treatment program in a specific catchment area. Operators commission one before signing a lease, filing a Certificate of Need, or closing on acquisition capital. The study tells you whether the program can clear state licensure, secure in-network contracts, and hit census targets inside a 12 to 18 month ramp.
The market needs the discipline. On July 28, 2025, SAMHSA released the 2024 National Survey on Drug Use and Health. SAMHSA Principal Deputy Assistant Secretary Dr. Art Kleinschmidt framed the release plainly: “The annual NSDUH provides timely statistical information on substance use and mental health in the U.S.”
The underlying number matters more than the framing. Among people 12 or older, 16.8% (or 48.4 million people) had a past-year substance use disorder, per SAMHSA. That sounds like green-field opportunity. It is not.
Operators in Palm Beach County and Asheville still close beds every quarter. The unmet-need number does not translate to commercially insured admissions inside a 25-mile drive radius. A feasibility study bridges the macro number to the seven-figure decision in front of you.
What actually goes in the deliverable
A real feasibility study is not a 40-page brochure. It is a defensible binder a lender, an investment committee, or a state surveyor can pressure-test. When our analysts at Atlantic Health Strategies build one, operators should see seven components, each tied to a downstream filing or contract.
- Catchment and demand modeling. Drive-time isochrones (typically 30, 60, and 90 minutes for residential; 20 minutes for outpatient), CDC WONDER county overdose mortality, and SAMHSA prevalence by MSA. Per NCHS Data Brief No. 549, in both 2023 and 2024, the drug overdose death rate was highest for adults ages 35-44 (60.8 and 44.2, respectively) and lowest for those ages 15-24 (13.5 and 8.5, respectively). Age band drives acuity mix. Acuity mix drives payer mix. Payer mix drives the pro forma.
- Competitive saturation. Existing bed counts by ASAM Criteria (4th Edition) level of care, drawn from SAMHSA’s N-SUMHSS, state licensure rosters, and on-the-ground call audits.
- Payer mix and rate modeling. Commercial penetration by carrier (Optum/UBH, Carelon, Aetna, Magellan), Medicaid MCO carve-outs, and modeled net revenue per patient day by HCPCS code (H0010 through H0019 for residential SUD, H0035 for PHP, H0015/S9480 for IOP).
- Licensure pathway with a clock. Which agency, which statute, what the survey looks like, and what the realistic effective date is.
- Accreditation runway. Joint Commission or CARF timing relative to license issuance and payer contracting.
- Real estate and zoning. Fair Housing Act and ADA reasonable accommodation analysis for residential SUD siting.
- Pro forma with sensitivity bands. Census ramp, denial rate, DSO, and labor cost stressed against base case.
How licensure and payer reality reshape the model
Two examples make the point. In Florida, DCF administers the regulatory process to license substance abuse service providers under Chapter 397, Florida Statutes and Chapter 65D-30, Florida Administrative Code, while AHCA licenses higher-acuity mental health facilities under Chapter 394. Compare that to North Carolina, where DHSR review timelines can stretch your effective date well past your lease commencement. Same building, same clinical model, completely different go/no-go math.
Payers move the model just as hard. KFF’s 25th annual Medicaid Budget Survey reports that total Medicaid spending grew by 8.6% in FY 2025 and is expected to grow by 7.9% in FY 2026, with states citing provider rate increases, greater enrollee health care needs, and growing costs for long-term care, pharmacy benefits and behavioral health services as key drivers of increased costs.
That sounds bullish until you sit with it. Nearly two-thirds of states say they face at least a “50-50” chance of a Medicaid budget shortfall in FY 2026 as they anticipate tighter fiscal conditions. States are also preparing for $911 billion in federal Medicaid spending cuts enacted in the budget reconciliation law. The trend line is decelerating, not accelerating.
IMD exclusion rules, state-specific rate floors, and MCO contracting cycles mean an operator in Kentucky and an operator in South Carolina face entirely different reimbursement realities for the same ASAM level. A feasibility study that does not name the MCO, the rate, and the credentialing timeline is not a feasibility study. It is a sales document. The narrow network is your problem to solve in diligence, not after Day 90.
What disqualifies a market, and what a study should tell you to walk away from
A feasibility study earns its fee when it tells you no. Real disqualifiers our analysts have flagged for clients in the last 18 months:
- Saturation at the level of care you want to build. If a 30-minute drive radius already has more than 1.5 licensed residential beds per 1,000 SUD prevalence, and three of the incumbents are in-network with the dominant commercial payer, your ramp will not pencil.
- A payer environment that will not credential a new TIN inside 9 months. CAQH credentialing benchmarks plus MCO contracting cycles tell you this before you sign anything.
- A site that cannot clear local zoning or fire marshal review. Founders in Texas and Tennessee have lost six figures in renovation spend because nobody pulled the zoning letter first.
- An overdose mortality trend moving against your acuity model. The CDC’s National Center for Health Statistics reported an estimated 80,391 drug overdose deaths in the United States during 2024, a decrease of 26.9% from the 110,037 deaths estimated in 2023. That is good news for public health. It also means a residential detox pro forma built on 2022 admission patterns is already stale. Per the same CDC release, Louisiana, Michigan, New Hampshire, Ohio, Virginia, West Virginia, and Wisconsin and Washington, D.C., experienced declines of 35% or more. If you underwrote a detox program in one of those markets on 2022 comps, your acuity assumptions are wrong.
- A founder team without a credentialed Medical Director or a defensible clinical leadership bench. No surveyor cares about your deck.
A study without the spine to recommend a no-go is not worth the engagement letter.
How AHS approaches feasibility engagements
When operators come to Atlantic Health Strategies at the feasibility stage, our analysts scope against the state you are actually building in, not a national template. Florida, North Carolina, Kentucky, South Carolina, Tennessee, and Texas each carry their own licensure clocks, zoning realities, and MCO panels. That specificity is the deliverable.
Our team names the surveyor focus by state. We model payer readiness against carrier-specific credentialing timelines. We stress the pro forma against denial rates and utilization management patterns that are real for your ASAM level of care, not aspirational. And when the answer is no, we say no in writing before you sign the lease.
A feasibility study is not the end of diligence. It is the document that decides whether the rest of the diligence is worth paying for. Build it once. Build it right.
Frequently asked questions
How much does a behavioral health feasibility study cost, and how long does it take?
For a single-site, single-level-of-care program, expect roughly $25,000 to $75,000 and 4 to 8 weeks. Multi-site, multi-state, or Certificate of Need engagements run higher and longer because the licensure analysis is bespoke per jurisdiction. A flat $7,500 quote is a market brief, not a feasibility study.
What is the difference between a feasibility study, a market study, and a Certificate of Need application?
A market study quantifies demand and competition. A feasibility study adds licensure pathway, payer modeling, pro forma, and real estate viability, and ends in a go / no-go / conditional recommendation. A Certificate of Need is a regulatory filing in CON states that draws on the feasibility work but is submitted to the state agency for approval to add capacity.
Should I commission a feasibility study before or after site selection?
Before. The site decision should be an output of the study, not an input. Operators in Kentucky and South Carolina have signed leases first and then discovered the zoning overlay or a closed MCO panel made the location unworkable.
Will a feasibility study tell me to walk away from a market?
A good one will. Saturation at your target ASAM level, a closed commercial payer panel, a non-permissive zoning environment, a state licensure timeline that breaks your construction draw schedule, or overdose mortality trends contradicting your acuity model are all walk-away triggers. Per CDC NCHS, an estimated 80,391 drug overdose deaths occurred in the United States in 2024, a 26.9% decrease from 110,037 in 2023, which means acuity assumptions built on 2022 data are already stale.
References
- SAMHSA, Releases Annual National Survey on Drug Use and Health (July 28, 2025)
- CDC NCHS, U.S. Overdose Deaths Decrease Almost 27% in 2024 (May 14, 2025)
- CDC NCHS Data Brief No. 549, Drug Overdose Deaths in the United States, 2023–2024
- KFF, 25th Annual Medicaid Budget Survey (November 13, 2025)
- KFF, Medicaid Enrollment & Spending Growth: FY 2025 & 2026
- Florida DCF, Substance Abuse Provider Licensure (Chapter 397, F.S. / Chapter 65D-30, F.A.C.)